cdr

Hot Keywords
Drug Resistance Mechanisms Epigenetic Resistance in Cancer Therapy Biomarkers Pharmacogenetics of Cancer Liquid Biopsy Targeted Cancer Therapy Non-coding RNAs Kinase Inhibitors ABC Transporters

Top

Junior Editorial Board

  • Advanced Bioscience Laboratories, Maryland, MD, USA.
    Research Interests: Cancer immunotherapy, T-cell biology, drug discovery, LAG3, MHC
  • Department of Biological Sciences, University of South Carolina, Columbia, USA.
    Research Interests: breast cancer biology; caner stem cells; microRNA; HER2-targeted therapy; immune escape mechanism;immunotherapy.
  • Department of Pharmacology, Faculty of Medicine, University of Malaya, Malaysia.
    Research Interests: cancer therapeutics; tumor microenvironment; cancer-associated fibroblasts; drug pharmacology; drug resistance.
  • Faculty of Medicine and Surgery, University Campus-Biomedico, Rome, Italy.
    Research Interests: mesothelioma, metformin; CSC; translational oncology; chemoresistance; TKI; Ephrin; EMT.
  • Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University,Olomouc, Czech Republic.
    Research Interests: anti-cancer drug repurposing; hypoxia; small molecules; three-dimensional cell cultures.
  • Universiteit Antwerpen, Antwerpen, Belgium.
    Research Interests: p53 pathway; non-small cell lung cancer; oxidative stress; PARP-1 inhibition; pancreatic cancer; targeted therapies.
  • Okayama University, Okayama, Japan.
    Research Interests: exosomes; extracellular vesicles; 3D culture systems; tumoroids; protein moonlighting; cancer; omics; gene regulation.
  • Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal.
    Research Interests: polymeric micelles; gene therapy; micelleplexes; controlled release.
  • University of South Alabama College of Medicine, University of South Alabama Mitchell Cancer Institute, Mobile, USA.
    Research Interests: triple negative breast cancer; DNA damage; DNA repair; base excision repair.
  • Sharda University, Greater Noida, India.
    Research Interests: bio/nanomaterial; cancer drug delivery; phytonanomedicine and tissuee engineering.
  • Department of Pharmacy, Abdul Wali Khan University Mardan, 23200, Pakistan.
    Research Interests: drug discovery from natural product; cancer treatment; molecular mechanisms of anticancer agents; anticancer drug resistance.
  • Department of Animal Nutrition, The Kielanowski Institute of Animal Physiology and Nutrition, Polish Academy of Sciences, Jabłonna, Poland.
    Research Interests: p53 gene; human cancers like liver and pancreas; oxidative stress in gastrointestinal tract; DNA repair; BER and NER pathway.
  • Department of Physiology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
    Research Interests: preclinical drug testing; cell death assays; cell signaling pathways; drug resistance mechanisms.
  • University of Padova and Pediatric Research Institute, Padua, Italy.
    Research Interests: high throughput drug screening (HTS); medulloblastoma; acute lymphoblastic leukemia; pediatric cancer; cell cycle; apoptosis; kinase inhibitors.
  • Department of Chemistry, Materials and Chemical Engineering “Giulio Natta”, Politecnico di Milano, Milan, Italy.
    Research Interests: cancer, theragnostics; targeted therapy; nanotechnology; nanomedicine; multifunctional nanomaterials; nanocarriers; drug delivery.
  • Hormel Institute, University of Minnesota, Austin, MN, USA.
    Research Interests: ovarian cancer; cell death; necroptosis; cancer stem cells; chemoresistance; metabolism; DNA damage and repair; ovary and brain.
  • The University of Adelaide, Adelaide, Australia.
    Research Interests: cancer biology; prostate cancer; lipid metabolism; angiogenesis and lymphangiogenesis; drug discovery.
  • Science For Life Laboratory, Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden.
    Research Interests: genome stability; DNA replication; DNA repair; nucleotide metabolism; cancer therapy; precision medicine; drug resistance; drug combinations.
  • Department of Cancer Biology, Mayo Clinic, Jacksonville, FL, USA.
    Research Interests: cancer biology; signaling pathways; biomarkers; apoptosis; PI3K/mTOR signaling; head and neck cancer; targeted therapy; ovarian cancer; stem cells.
  • Department of Molecular Pathology, Hiroshima University,Hiroshima, Japan.
    Research Interests: prostate cancer; renal cell carcinoma; bladder cancer; immunohistochemistry; drug resistance; and molecular biology.
  • Department of Cell Biology & Institute of Biomedicine, College of Life Science and Technology, Jinan University, China
    Research Interests: cancer drug resistance, anticancer drugs, cancer biomarker, cancer cell biology, protein-protein interaction, protein modification.
  • Department of Biochemistry and Molecular Biology, College of Natural Sciences, Colorado State University, Fort Collins, CO, USA.
    Research Interests: cell migration; actin cytoskeleton; ADF/cofilin; breast cancer; triple negative breast cancer; androgen receptor; targeted therapy.
  • International society of cancer metabolism, European Society for Free Radical Research, Department of Medical Biology, Centre Scientifique de Monaco, Monaco.
    Research Interests: ferroptosis; amino acid transporters; cancer; redox regulation; oxidative stress; metabolism.
  • Department of Biological and Biomedical Sciences, Glasgow Caledonian University, Scotland, United Kingdom.
    Research Interests: acute lymphoblastic leukaemia; multiple myeloma; acute myeloid leukaemia; chemotherapy resistance.
  • Digestive Disease Research Group, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA, USA.
    Research Interests: colon cancer therapeutics; biomimetic nano delivery systems; targeted drug delivery; digestive disease.
  • Harvard Medical School, Boston, MA, USA.
    Research Interests: prostate cancer, cancer metabolism, metabolic imaging, metabolomics, diet&lipid metabolism, cancer microenvironment, resistance to endocrine therapies, cancer progression.
close
© 2016-2021 OAE Publishing Inc., except certain content provided by third parties